ArriVent BioPharma, Inc.
AVBP
Rank in Stocks
#10422
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages... ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company’s lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
Share Price
$14.16
Last synced: 2026-11-09
Market Cap
$698.20M
Change (1 day)
3.81%
Change (1 year)
-29.90%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade ArriVent BioPharma, Inc. (AVBP)
Category
Healthcare
EPS for ArriVent BioPharma, Inc. (AVBP)
EPS as of June 2026 TTM: $-3.68
According to ArriVent BioPharma, Inc.'s latest financial reports, its current EPS (TTM) is $-3.68. At the end of 2025 the company had an EPS of $-4.32, a decrease compared to its 2024 EPS of $-2.56.
EPS history for ArriVent BioPharma, Inc. from 2021 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.68 | -14.81% |
| 2025 | $-4.32 | 68.75% |
| 2024 | $-2.56 | 17.97% |
| 2023 | $-2.17 | 97.27% |
| 2022 | $-1.10 | -97.28% |
| 2021 | $-40.44 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -525.54% |
US
|
|
| $-7.07 | 92.12% |
US
|
|
| $-5.29 | 43.75% |
AU
|
|
| $12.88 | -450.00% |
BE
|
|
| $21.56 | -685.87% |
NL
|
Questions about ArriVent BioPharma, Inc.'s earnings per share (EPS)
What is ArriVent BioPharma, Inc.'s earnings per share (EPS)?
ArriVent BioPharma, Inc.'s earnings per share (EPS) over the last twelve months is $-3.68, as of Jun 2026.
What was ArriVent BioPharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, ArriVent BioPharma, Inc.'s earnings per share (EPS) was $-4.32, compared with $-2.56 in 2024.
How has ArriVent BioPharma, Inc.'s earnings per share (EPS) changed since 2021?
From 2021 to 2025, ArriVent BioPharma, Inc.'s earnings per share (EPS) was highest in 2022 ($-1.10) and lowest in 2021 ($-40.44).
How does ArriVent BioPharma, Inc.'s earnings per share (EPS) compare with similar companies?
ArriVent BioPharma, Inc.'s earnings per share (EPS) ($-3.68) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.